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AGO Recommendations for Diagnosis and Treatment of 
Patients with Advanced and Metastatic Breast Cancer: 
Update 2013
Nadia Harbecka Anton Scharlb Christoph Thomssenc Volkmar Müllerd;  
on behalf of the AGO Breast Committee*
aBrustzentrum, Frauenklinik, Universität München, bFrauenklinik, Klinikum Amberg, cFrauenklinik, Martin-Luther Universität Halle/Saale,
dKlinik für Gynäkologie, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany
for their scientific validity (Oxford Level of Evidence, LoE; 
www.cebm.net [1]) and clinical relevance (AGO Grades of 
Recommendation; table 1). All AGO Breast Committee 
members have declared their potential conflicts of interest. 
Here, we present the 2013 update of these guidelines focus-
sing on changes made this year. The full version of the 2013 
update is available online as a PDF file [2] in an English and a 
German version. Moreover, a version for patients is also 
available at www.ago-online.de.
Locoregional Recurrence
On average, 5–10% of primary breast cancer patients will 
 develop locoregional recurrence after primary adjuvant treat-
ment. The molecular subtype is an important risk factor. 
 Patients with triple-negative or human epidermal growth 
 factor receptor 2 (HER2)-positive subtype are more likely to 
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Introduction
For the last 12 years, the Breast Committee of the Arbeits-
gemeinschaft Gynäkologische Onkologie (German Gynaeco-
logical Oncology Group, AGO) has issued annually updated 
evidence-based recommendations for the diagnosis and 
 treatment of patients with early and metastatic breast cancer. 
The AGO Breast Committee consists of 43 gynaecological 
oncologists specialized in breast cancer and interdisciplinary 
members specialized in pathology, radiological diagnostics, 
medical oncology and radiotherapy. Each update is per-
formed  according to documented rules by thoroughly review-
ing and scoring chapter by chapter the recent publications 
* Members of the ‘AGO Breast Committee’ in alphabetical order: Ute-Susan Albert, Marburg; Ingo Bauerfeind, Landshut; Joachim Bischoff, 
 Magdeburg; Jens Uwe Blohmer, Berlin; Klaus Brunnert,  Osnabrück; Peter Dall, Lüneburg; Ingo J. Diel, Mannheim; Tanja Fehm, Düsseldorf;  
Nikos Fersis, Chemnitz; Michael Friedrich, Krefeld; Kay Friedrichs, Hamburg; Bernd Gerber, Rostock; Volker Hanf, Fürth; Nadia Harbeck, 
München; Jens Huober, Ulm; Christian Jackisch,  Offenbach; Wolfgang Janni, Ulm (Co-Chair); Walter Jonat, Kiel (DKH); Hans H. Kreipe,  
Hannover (DGP); Sherko Kümmel, Essen; Sibylle Loibl, Neu-Isenburg; Hans-Joachim Lück, Hannover; Michael Lux,  Erlangen; Nicolai Maass, 
Aachen; Gunter von Minckwitz, Neu-Isenburg; Volker Möbus, Frankfurt; Christoph Mundhenke, Kiel; Volkmar Müller, Hamburg; Ulrike Nitz, 
Mönchengladbach; Mahdi Rezai, Düsseldorf; Achim Rody, Lübeck; Anton Scharl, Amberg (Chair); Rita Schmutzler, Köln; Marcus Schmidt, Mainz; 
Andreas Schneeweiß, Heidelberg (AIO); Ingrid Schreer, Hamburg (DGS); Florian Schütz, Heidelberg; Peter Sinn, Heidelberg (Pathologie);  
Erich F. Solomayer, Homburg; Rainer Souchon, Tübingen (ARO); Elmar Stickeler, Freiburg; Christoph Thomssen, Halle (Saale); Michael Untch, 
Berlin
Table 1. AGO grades of recommendation
++ This investigation or therapeutic intervention is highly beneficial for patients, can be recommended without restriction, and should be 
performed.
+ This investigation or therapeutic intervention is of limited benefit for patients and can be performed.
+/– This investigation or therapeutic intervention has not shown benefit for patients and may be performed only in individual cases.  
According to current knowledge a general recommendation cannot be given.
– This investigation or therapeutic intervention can be of disadvantage for patients and might not be performed.
–/– This investigation or therapeutic intervention is of clear disadvantage for patients and should be avoided or omitted in any case.
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develop local recurrence compared to those with luminal A/B 
subtype [3]. To avoid ‘overtreatment’ or ‘undertreatment’ and 
to prevent complications, restaging is recommended. In addi-
tion, the recurrence should be confirmed by a biopsy, and the 
predictive markers including oestrogen receptor (ER), pro-
gesterone receptor (PR) and HER2 should be re-evaluated. 
The aim of surgery is to achieve an ‘in sano resection’. The 
management of the axilla is challenging. In a cN0 situation, 
performing sentinel lymph node biopsy (SLNB) during re-
lapse surgery (second SLNB) after previous SLNB is techni-
cally feasible [4, 5]. However, if no sentinel can be identified, 
axillary lymph node dissection should not be performed. Only 
if axillary lymph nodes are suspicious, exploratory axillary 
dissection is indicated. Irradiation of the axilla in the case of 
axillary recurrence depends on previous treatment and should 
be individually discussed. Cytotoxic treatment should be 
 offered particularly to those patients who are hormone recep-
tor (HR)-negative based on the results of the CALOR trial 
[6]. ‘Adjuvant’ chemotherapy resulted in a significant benefit 
for disease-free survival (DFS) and overall survival (OS) fol-
lowing isolated locoregional recurrence compared to no 
chemotherapy. HER2-targeted therapy and endocrine ther-
apy are recommended in HER2-positive and in HR-positive 
patients, respectively. In non-curative cases and where there 
is a lack of other therapeutic options, combination of radio-
therapy and hyperthermia improves the clinical response rate 
but should only be performed in expert centres (as listed on 
the website of the Deutsche Krebsgesellschaft, DKG) [7]. 
Other options are chemotherapy combined with hyperther-
mia, electrochemotherapy and photodynamic therapy, which 
may provide clinical benefit in individual patients [8, 9].
Endocrine and Targeted Therapy  
in Metastatic Breast Cancer
Endocrine therapy in metastatic breast cancer remains the 
therapy of choice in HR-positive disease. If feasible, a biopsy 
from the metastatic lesion should be taken. Recent prospec-
tive and retrospective data indicate a receptor shift in about 
15% for ER, between 25–40% for PR, and in less than 10% 
for the HER2 status [10–13].
HER2-Negative Metastatic Breast Cancer
In premenopausal patients the possible therapeutic option of 
a luteinizing hormone-releasing hormone (LHRH) analogue 
in combination with fulvestrant has been included. Although 
only 26 patients in different lines have been treated with that 
combination as reported recently, the treatment option has 
been included [14]. 
In postmenopausal patients there are several endocrine 
treatment options. The updated analysis of the CONFIRM 
study supports the use of 500 mg fulvestrant. After adjuvant 
aromatase inhibitor (AI), it has become one of the preferred 
options in the 1st or 2nd line endocrine treatment for primary 
breast cancer. 250 mg fulvestrant remains an option which has 
been proven equally effective as an AI [15]. 2 trials reported 
their final analysis on the combination of fulvestrant 250 mg 
plus anastrozole vs. anastrozole alone. The US trial per-
formed by the SWOG group indicated a significant prolonged 
progression-free survival (PFS) and OS for the combination 
[16], whereas the FACT study could not confirm these find-
ings [17]. Due to these conflicting results the combination 
after adjuvant tamoxifen was considered an option (+/–). 
The combination of everolimus and exemestane is been 
recommended for 2nd line therapy in women who have re-
ceived tamoxifen as adjuvant therapy. For women who have 
already been treated with a non-steroidal AI in the adjuvant 
setting and have relapsed within 12 months, everolimus plus 
exemestane is one recommended treatment option. 
Termsirolimus plus letrozole however is not a treatment op-
tion [18] (figs. 1 and 2). The combination of everolimus plus 
tamoxifen has been upgraded as a treatment recommendation 
based on the data of the TAMRAD study [19, 20]. 
Fig. 1. Therapy algorithm after adjuvant tamoxifen.
Fig. 2. Therapy algorithm after adjuvant aromatase inhibitor (AI).
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The combination of an endocrine therapy plus bevaci-
zumab has not been proven to be superior to endocrine ther-
apy (mostly letrozole) alone [21, 22]. 
HER2+ Metastatic Breast Cancer 
HER2+ HR-positive breast cancer can generally be treated 
with an endocrine therapy in combination with an anti-HER2 
agent. There are no new data supporting that concept. How-
ever, with the dual anti-HER2 blockade at the horizon this 
might change. So far, there are no data for metastatic breast 
cancer to support this concept.
Chemotherapy with or without Targeted Drugs  
in Metastatic Breast Cancer
For the 2013 update, we have combined the chapters ‘chemo-
therapy’ and ‘targeted therapy’ for metastatic breast cancer, 
acknowledging the increasing role of targeted therapies which 
are generally given in combination with standard endocrine or 
cytotoxic therapies and provide survival benefit in some 
 circumstances (LoE 1b). Similar to the treatment selection in 
the adjuvant situation, also in advanced disease, tumour 
 biology is considered relevant for therapy decisions. The 
choice of treatment depends on i) ER/PR, HER2; combina-
tion with compounds of targeted treatment; ii) previous treat-
ments (and their toxicities); iii) aggressiveness of disease and 
location of metastases; iv) biologic age; v) co-morbidities 
 (including organ dysfunction); and vi) patient preference and 
expectations.
First-line therapy in ER-positive tumours is generally 
 endocrine therapy. If the disease has been proven to be 
ER-negative (preferentially diagnosed by biopsy of at least 
1 metastatic lesion), or if the course of the disease suggests 
endocrine resistance or urgent need of response, cytotoxic 
chemotherapy is indicated (LoE 1aA, AGO++). This is in 
 accordance with recently published First International Con-
sensus Guidelines for Advanced Breast Cancer (ABC 1) [23]. 
The use of anthracyclines (including liposomal anthracy-
clines) and taxanes remains state of the art in 1st-line therapy 
of metastatic breast cancer. Vinorelbine, capecitabine and 
nab-paclitaxel are reasonable alternatives. Monotherapy is 
preferred over polychemotherapy in non-life-threatening situ-
ations. Particularly in single-agent therapy, it is recommended 
to treat as long as the therapeutic index remains positive (LoE 
2bB, AGO+). Monitoring of treatment response should be 
performed by assessing tumour burden at baseline and 
 approximately every 2 months, i.e. every 2–4 cycles of treat-
ment. Assessment of a target lesion may be sufficient. In slow 
growing disease, longer intervals are acceptable (AGO++). 
Although some evidence is already available, determination 
of circulating tumour cells is still considered experimental and 
recommended preferentially within clinical trials (LoE 1bA, 
AGO+).
In some situations, e.g. in triple-negative breast cancer or 
other aggressive situations, combination of chemotherapy 
with bevacizumab can be recommended to increase the re-
sponse rate and PFS although not prolonging survival (LoE 
2bB, AGO+) [24]. The combination of chemotherapy with 
other targeted drugs (e.g. sunitinib, sorafinib, vantetanib) is 
experimental and should not be performed outside of clinical 
trials. Platinum-based chemotherapy may be useful as further-
line treatment especially in triple-negative breast cancer (LoE 
2bB, AGO+/–), even though data from prospective rand-
omized trials are still lacking.
The biggest step forward in the treatment of metastatic 
breast cancer has been achieved in HER2-overexpressing dis-
ease. Recently, pertuzumab was registered in the European 
market for 1st-line patients as a triplet together with trastu-
zumab and docetaxel. Approval was based on emerging data 
of the phase III CLEOPATRA trial that demonstrated an im-
provement of PFS (primary endpoint) and OS compared to 
docetaxel and trastuzumab alone [25]. 
In the light of this upcoming 1st-line standard, the sequen-
tial use of anti-HER2 drugs needs to be redefined in the near 
future. In this context, introduction of trastuzumab emtansine 
(T-DM1) as a further option is eagerly awaited. T-DM1 is the 
first member of a new class of antibody-drug conjugates 
(ADC) with proven activity in solid tumours. It is composed 
of trastuzumab, a stable linker molecule, and the cytotoxic 
DM1 (derivate of maytansine). As a consequence, T-DM1 
combines the distinct mechanisms of action of both DM1 and 
trastuzumab. Clinical relevance of these findings has been 
demonstrated in the pivotal EMILIA trial that focused pref-
erentially on heavily pretreated BC patients. One of the main 
inclusion criteria was pre-exposure to taxanes and trastu-
zumab. The recently published results indicate that T-DM1 is 
superior to lapatinib and capecitabine in terms of PFS and 
OS. Furthermore, toxicity was analysed as another endpoint, 
suggesting that the experimental compound was better toler-
ated [26, 27]. With respect to its favourable safety profile, 
T-DM1 represents the next step in modern targeted drug 
 design in order to minimize chemotherapy-induced side ef-
fects in HER2-positive patients.
Specific Sites of Metastases
Specific sites of breast cancer metastases are liver, lung, 
pleura, pericardium, peritoneum, bone marrow, or any soft 
tissue. Other rare locations like adrenals, ovaries, uterus, 
stomach, colon, or placenta have also been reported. In such 
rare cases, controlled trials are not eligible, and treatment 
 options must be discussed individually. 
Management of primary stage IV breast cancer focuses on 
systemic therapy. The impact of the extent of local treatment 
on OS is still under discussion. Some trials have suggested an 
association between local treatment (surgery or radiotherapy) 
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of the primary tumour and prolonged survival, whereas there 
are other reports that did not [28]. However, many questions 
remain, such as whether these results reflect a selection of 
women with good prognosis for primary site therapy; other 
questions address the fraction of women in published studies 
who were diagnosed with metastatic disease only after sur-
gery, whether specific subsets of metastases and biological 
subtypes would derive greater benefit, and the appropriate 
timing and extent of local therapy. If surgery of the primary 
tumour is performed in the metastatic setting, local excision 
or mastectomy should be done with tumour-free margins [29–
33]. Axillary surgery is only indicated for bulky disease. 
Systemic treatment of metastatic disease is the therapy 
of choice. Before treatment, metastases should be confirmed 
by histology to re-evaluate diagnosis, HR and HER2 status. 
A shift in these markers occurs in nearly 20% and has an im-
pact on systemic treatment. If surgery for distant metastases is 
considered, good overall health, oligometastasis and a long 
time between primary treatment and the occurrence of metas-
tases are all favourable factors regarding outcome. Resection 
of liver metastases may be performed after histological verifi-
cation if R0 resection is feasible, if no extrahepatic metastases 
were present, and in patients who had HR-positive breast 
cancer and a good response to former chemotherapy [34, 35]. 
Other procedures like regional radiotherapy, thermoablation 
or chemoembolization are also possible in individual cases 
[36, 37]. 
For proven pulmonary metastases, the LoE for a curative 
approach is low, but some patients might benefit from a me-
tastasectomy followed by an appropriate systemic treatment 
[38]. In accordance with the treatment of liver metastases, 
 resection of lung metastases should only be performed if R0 
resection is feasible and if histological verification was done. 
The timing of any local intervention may be critical; resection 
before progression is associated with a better outcome.
About 10% of all breast cancer patients develop malignant 
pleural effusion (MPE). In almost 50% of MPE it is the first 
sign of metastatic disease, resulting in dyspnoea and reduced 
subjective well-being. It should be treated in symptomatic 
cases exclusively. Thoracoscopy with talcum pleurodesis 
(VATS) is the option of choice for MPE. Other sclerosing but 
more rarely used agents are bleomycine, doxycycline and 
 mitoxantrone [39]. Continuous pleural drainage with indwell-
ing pleural catheters is a well-tolerated and safe treatment 
 alternative for patients who are not candidates for VATS. 
 Catumaxomab is not yet recommended for MPE. 
Overall, 3% of breast cancer patients will suffer from 
 malignant ascites. Management of ascites takes place in the 
context of palliative care, and aims at improving the quality of 
life of these patients. Patients with symptomatic ascites should 
undergo drainage. Local antibody therapy with catumaxomab 
[40] remains an option in individual cases. 
Malignant pericardial effusion and cardiac tamponade 
 remains a rarity in breast cancer patients. In symptomatic 
 patients, drainage and pericardial fenestration are probably 
the treatment options of choice. For individual patients, 
VATS or ultrasound-guided puncture with instillation of 
 mitoxantrone or bleomycine may be an alternative [41]. 
The choice between supportive care or specific anticancer 
treatment for poor performance status breast cancer patients 
with multimetastatic disease and pancytopenia due to bone 
marrow involvement often remains a clinical and human 
 dilemma. Depending on the underlying cancer biology, endo-
crine or chemotherapy or antibody treatment options should 
be reconsidered [42]. It has been reported that aggressive 
combination treatment regimens were effective since most 
 patients show improved marrow function after chemotherapy, 
and prolonged survival could be possible.
Soft Tissue Metastasis – Local Radiotherapy
Local radiotherapy is the most important treatment for pa-
tients with paresis or spinal cord compression, who cannot be 
operated on or have failed to respond to systemic treatment 
[43]. Even after surgery, concomitant radiotherapy and sys-
temic treatment are indicated. Plexus infiltration and other 
inoperable soft tissue metastasis should be treated with 
radiotherapy.
Central Nervous System Metastases in Breast Cancer
Metastatic spread to the central nervous system is an increas-
ing problem in triple-negative breast cancer as well as in 
HER2-positive disease. Nevertheless, screening for asympto-
matic brain metastases (BM) on a routine basis is not recom-
mended in breast cancer. A key problem is that most studies 
examining the treatment of BM did not focus on breast can-
cer. For many years, it has been debated whether patients 
with a limited number of BM may benefit from whole brain 
radiation therapy (WBRT) after local treatment of these le-
sions. A recent meta-analysis suggests that the standard of 
care in BM is 3,000 cGy in 10 daily fractions or 2,000 cGy in 
4–5 daily fractions (LOE 1a, AGO++) [44]. Consistent with 
the 2012 recommendations, surgical procedures should be 
limited to individuals presenting with clinical symptoms or 
complications due to the location of the metastases. Evidence 
is suggesting that this is an individualized procedure as sur-
vival is not improved. The same Cochrane meta-analysis pro-
vides no evidence that combination of WBRT with either 
 radiosensitizers or chemotherapy is of any benefit over 
WBRT alone [44]. In asymptomatic individuals with BM 
overexpressing HER2, the use of lapatinib and capecitabine 
may be an option to reduce signs and symptoms as well as to 
postpone the onset of WBRT as demonstrated in a phase II 
trial (LOE 2b, B; AGO+) [45].
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